Short answer
Tenaya Therapeutics Inc (TNYA) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Tenaya’s earnings release covers the quarter ended September 30, 2026.
Tenaya Therapeutics Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Tenaya’s earnings release covers the quarter ended September 30, 2026
- Exhibit 99.1 contains the financial results and management disclosures relevant to investors
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 net loss $18.9M, or $0.08 per share, improved from $20.3M, or $0.12, year over year
- Cash $66.8M supports planned operations into Q4 2027, reducing near-term financing pressure but not eliminating funding risk
- TN-401 received FDA RMAT designation, potentially enabling closer regulatory interaction for PKP2-associated ARVC development
- Year-end readouts for TN-201 and TN-401 include one-year Cohort 2 data and durability data for Cohort 1
- TN-301 study-enabling work targets at least one company-sponsored Phase 2 trial in the second half of 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tenaya Therapeutics Inc 8-K filings
Get the next TNYA 8-K as it lands
Follow TNYA for push alerts, or ask the research agent what this filing means.